# Standardized Berry Extract Improves Selected Visual Function Outcomes in Presbyopia: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial with Exploratory Biomarker Analysis

**Authors:** Dorota Szumny, Alicja Zofia Kucharska, Karolina Czajor, Karolina Kaptsiuh, Sabina Ziółkowska, Patrycja Krzyżanowska-Berkowska, Marta Misiuk-Hojło, Monika Skrzypiec-Spring, Jakub Szyller, Adam Szeląg, Tomasz Sozański

PMC · DOI: 10.3390/nu18061016 · Nutrients · 2026-03-23

## TL;DR

A berry extract improved some vision-related outcomes in older adults, but more research is needed to confirm its effects.

## Contribution

This is the first study to show potential visual and biomarker effects of a standardized berry extract in presbyopia.

## Key findings

- AKB improved near contrast sensitivity and visual-field parameters compared to placebo.
- AKB was associated with lower αA-/αB-crystallin and ALDH1A1 levels and higher TRPV4 levels.
- Systemic antioxidant enzymes and advanced glycation end-products were unchanged by AKB.

## Abstract

Background/Objectives: Presbyopia is an age-related decline in near vision associated with lens stiffening and neuroretinal changes, while evidence for the effects of berry-derived phytochemicals remains limited. We investigated whether AKB, a double-standardised berry extract (anthocyanins ≥ 25%, iridoids ≥ 4.5%) from Aronia melanocarpa, Lonicera caerulea, and Vaccinium myrtillus, influences visual performance and circulating biomarkers potentially relevant to ocular homeostasis. Methods: In a randomised, double-blind, placebo-controlled, two-period crossover trial, 23 adults aged >50 years received AKB (400 mg twice daily) or placebo for 6 weeks, separated by a 5-week washout. Results: Compared with placebo, AKB was associated with improvements in selected visual-function outcomes, including near contrast sensitivity and visual-field parameters, together with directionally favourable changes in VEP and OCT readouts. AKB supplementation was also associated with lower circulating αA-/αB-crystallin and ALDH1A1 levels and higher circulating TRPV4 levels, whereas systemic antioxidant enzymes and advanced glycation end-products remained unchanged. Given the small sample size and the indirect nature of the biomarker assessment, these findings should be considered preliminary. Conclusions: Overall, short-term AKB supplementation was associated with modest, exploratory changes in selected functional and systemic biomarker outcomes, but larger and longer-term studies are needed to confirm clinical relevance and clarify underlying mechanisms.

## Linked entities

- **Genes:** ALDH1A1 (aldehyde dehydrogenase 1 family member A1) [NCBI Gene 216], TRPV4 (transient receptor potential cation channel subfamily V member 4) [NCBI Gene 59341]
- **Chemicals:** anthocyanins (PubChem CID 145858), iridoids (PubChem CID 453214)
- **Diseases:** presbyopia (MONDO:0001330)

## Full-text entities

- **Genes:** TRPV4 (transient receptor potential cation channel subfamily V member 4) [NCBI Gene 59341] {aka BCYM3, CMT2C, HMSN2C, OTRPC4, SMAL, SPSMA}, CRYAB (crystallin alpha B) [NCBI Gene 1410] {aka CMD1II, CRYA2, CTPP2, CTRCT16, HEL-S-101, HSPB5}, ALDH1A1 (aldehyde dehydrogenase 1 family member A1) [NCBI Gene 216] {aka ALDC, ALDH-E1, ALDH1, ALDH11, HEL-9, HEL-S-53e}
- **Diseases:** Presbyopia (MESH:D011305)
- **Chemicals:** AKB (-), iridoids (MESH:D039823), anthocyanins (MESH:D000872)
- **Species:** Aronia melanocarpa (black chokeberry, species) [taxon 661339], Lonicera caerulea (blue honeysuckle, species) [taxon 134520], Vaccinium myrtillus (bilberry, species) [taxon 180763]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13028795/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13028795/full.md

## References

61 references — full list in the complete paper: https://tomesphere.com/paper/PMC13028795/full.md

---
Source: https://tomesphere.com/paper/PMC13028795